Knee Arthritis Is Not Just Wear and Tear: Why Inflammation Drives Pain and Progression
- 55 minutes ago
- 9 min read
By Dr. Jeffrey Peng, MD · Published July 24, 2026 · 9 min read
Watch the Full Video
If you have knee osteoarthritis, you have almost certainly been told it is wear and tear — cartilage grinding down, bone against bone, and pain as the mechanical price of a worn-out joint. Much of that is true. It is also incomplete.
The pain you feel and the speed at which your arthritis progresses are both tied closely to something else happening inside the joint: inflammation. Understanding that changes which treatments are worth trying — including for patients who have been told there is nothing left to try.
In my practice as a sports medicine physician in the San Francisco Bay Area, I have treated thousands of people with osteoarthritis, including many who arrived having been told they were bone-on-bone and out of options.
What Is Actually Happening Inside an Arthritic Knee?
A healthy joint works like a well-oiled machine. The ends of the bones are capped with articular cartilage, which allows the joint to glide with almost no friction. Osteoarthritis is, by definition, the gradual loss of that cartilage.
Radiographically we grade it from 0 to 4. Grade 0 is a clean joint. Grade 4 is bone-on-bone — so little cartilage remains that the space between the bones has collapsed on X-ray.
If Cartilage Has No Nerve Endings, Where Does the Pain Come From?
The intuitive answer is friction. When two rough surfaces grind against each other, pain seems inevitable, and mechanical load is genuinely part of the problem. But here is the detail that reframes everything: articular cartilage contains no nerve endings. You could scrape it directly and it would not hurt. The pain cannot be coming from the cartilage itself wearing down.
When roughened surfaces grind against one another, they provoke a reaction. The synovium — the lining of the joint — becomes inflamed. The joint swells, and the biochemical environment inside it turns hostile. It is that inflammation, not the grinding itself, that lights up the nerves surrounding the joint. This is why osteoarthritis is now understood as a disease of the entire joint rather than a cartilage problem.
This distinction matters enormously. If pain came only from worn cartilage, then once that cartilage was gone you would be stuck — which is exactly what many patients are told. The cartilage is gone, and the only remaining option is to wait until things are bad enough for a joint replacement.
So they wait. They stop moving. The muscles around the knee weaken, the joint stiffens, and the whole process accelerates. That is the real cost of the wear-and-tear story: it does not simply describe the problem, it talks patients out of the things that could still help. If the pain is driven substantially by inflammation, that changes the picture — because inflammation is something we can work on.
Why Don't X-Rays Predict Who Has Knee Pain?
If you take a room full of people and look only at their knee X-rays, the images do a surprisingly poor job of identifying who is actually in pain. Two people can have nearly identical X-rays, with one almost asymptomatic and the other barely able to walk.
There are two main reasons. First, an X-ray cannot show how inflamed the joint is. Second, the degree to which the nervous system has become sensitized strongly predicts pain — a joint that has hurt for a long time effectively turns up the volume, so the same signal is experienced as louder and more painful.
Your X-ray shows the degree of structural degeneration. It does not show the inflammation inside the knee, and it does not show how sensitized the nerves have become. Those are the things that track most closely with what you actually feel.
Does Inflammation Also Drive Arthritis to Get Worse?
Pain is one question. Progression is another. Rather than looking at the joint, one group of researchers looked at the blood. They measured inflammatory activity in the bloodstream of people with knee osteoarthritis and then followed them over time to see whose arthritis actually worsened.
They identified a group whose blood showed elevated levels of an inflammatory signal called IL-1 beta. Those patients did not just report more pain — they were at substantially higher risk of radiographic worsening over the following two years.
An important caveat: this is an association, not proof of causation. People with higher underlying inflammation also tend to carry more weight and have more metabolic disease, and those factors muddy the picture. What it shows clearly is that inflammation measurable on bloodwork tracks with, and predicts, who develops worse arthritis over time.
Why Did Drugs Built to Block Inflammation Fail?
If inflammation drives pain and damage, and if a molecule like IL-1 predicts who worsens, the obvious next step is to block it. That is exactly what was attempted. Researchers built a drug to block IL-1 and injected it directly into arthritic knees. It worked no better than placebo. A more potent IL-1 blocker was then administered for a full year. It failed on pain and failed on joint imaging — despite bloodwork confirming the drug was doing its job and lowering inflammation.
Consider how strange that is. These drugs measurably lowered inflammation, and the arthritis did not care. For a while the field drew the natural conclusion that inflammation must not be the real driver. That conclusion was wrong, and understanding why is the key to everything that follows.
Arthritis inflammation is not a single signal you can switch off. It is a web — dozens of overlapping molecules reinforcing one another. Block one completely, and the others simply route around it. The problem was never that inflammation does not matter. The problem was the strategy. You cannot block your way out of a web like this.
What Happened When Researchers Measured PRP's Effect on Blood Biomarkers?
That raises a different question. Instead of blocking one signal, what if you could shift the entire environment inside the joint at once? A recently published clinical trial tested precisely that idea. Every participant had late-stage arthritis — grades 3 and 4 — and every one was already on the waiting list for a knee replacement. They were divided into three groups: two PRP injections spaced one week apart, a cortisone injection, or oral anti-inflammatory medication.
What set this study apart is that it did not only track pain, function, and stiffness. Researchers drew blood at baseline, at three months, and at six months, measuring an entire panel of biomarkers — some that rise when cartilage is actively breaking down and the joint is inflamed, others that rise when the joint is shifting toward repair. For the first time, we can line up how patients felt against what the treatment was doing to their biology.
The clinical results came first: the PRP group had significant pain relief and better function, sustained through six months. The cortisone and oral medication groups did not come close. In patients with severe knee osteoarthritis, that alone is notable.
The biomarkers are the more interesting part. Among the destructive markers — COMP, which appears when cartilage is being degraded; IL-6 and TNF-alpha, the inflammatory drivers; and CGRP, which amplifies pain — all dropped at three months in the PRP group, and the key ones, COMP and IL-6, were still down at six months. Protective markers such as TGF-beta-1, which rise as a joint attempts to repair itself, went up. In the cortisone and oral medication groups, the biomarkers barely moved.
This is a single study, and the findings need replication in larger trials before anyone treats them as settled. But consider what it would mean if it holds. Osteoarthritis was never a sealed-off mechanical part wearing down in isolation — it is connected to the rest of the body through inflammation. Every drug that failed was built to block one signal in that web. PRP did not block a single signal; it appeared to shift the whole environment at once.
Does the Dose of PRP Matter?
The trial above used a standard PRP preparation, and it cannot speak to what happens at higher concentrations. This is where I will add something from my own practice rather than from the study. In severe osteoarthritic knees, the number of platelets actually delivered is often the difference between a knee that responds and one that does not. I have had well over a hundred patients try both a standard dose and a much higher-concentration dose, and almost none have wanted to go back down.
Is Knee Osteoarthritis Also a Metabolic Disease?
Return to where we started. You have been told osteoarthritis is wear and tear, a purely mechanical problem, and that once the cartilage is gone you are out of options. That explanation is incomplete. Inflammation plays a major role in how people experience joint pain — and osteoarthritis turns out to be as much a metabolic problem as a mechanical one.
Triglycerides, blood pressure, body fat percentage, and cholesterol all feed systemic low-grade inflammation. Left unchecked, that background inflammation makes an arthritic joint considerably more susceptible to pain.
Body fat is a useful example, because fat tissue is metabolically active. It releases inflammatory signaling molecules called adipokines — including leptin, TNF-alpha, and IL-6 — that drive chronic low-grade inflammation throughout the body. That inflammation weakens cartilage, worsens arthritis, and intensifies pain. It also explains why people with high body fat percentages or metabolic syndrome frequently develop osteoarthritis in joints that bear no weight at all, such as the hands.
Count how many of these apply to you: a large waist circumference, high blood pressure, high triglycerides, low HDL cholesterol, and high blood sugar. Three or more meets the definition of metabolic syndrome. If that is you, every one of those items is modifiable — and it is worth attention, because people with metabolic syndrome consistently show worse arthritis symptoms, greater cartilage degeneration, and more severe bone and joint changes. Improving metabolic health is a critical part of improving arthritis outcomes.
Can GLP-1 Weight-Loss Medications Help Knee Arthritis?
This is why newer GLP-1 medications have entered the arthritis conversation. In a large randomized trial, people with obesity and knee osteoarthritis who took semaglutide — the drug marketed as Ozempic or Wegovy — had significantly more pain relief than those on placebo. An important caveat: those patients also lost roughly 14 percent of their body weight, so the drug's direct effect cannot be cleanly separated from the effect of the weight loss itself. But for our purposes, that is rather the point. Shedding that fat means shedding a source of chronic inflammation, and the arthritis improved alongside it.
The implications extend past symptoms. Another group examined whether GLP-1 medications affect who ultimately needs knee replacement surgery. Drawing on data from tens of thousands of patients with knee arthritis, they compared those on a GLP-1 medication against similar patients who were not. Patients taking semaglutide or tirzepatide for three years saw their risk of surgery fall by nearly 30 percent. This was a database study rather than a randomized trial, so it demonstrates association rather than proof.
How I Approach Bone-on-Bone Knee Arthritis in My Practice
A patient I saw recently is a good illustration. Bone-on-bone in both knees, already evaluated by a knee replacement surgeon, and told there was nothing worth trying in the meantime. That is almost exactly the patient these studies were built around.
What I told her is that managing arthritis is not only about managing load — it is about actively controlling inflammation, which requires a multimodal approach. We build muscle strength in the legs, because strong muscles stabilize the joint and act as shock absorbers, reducing mechanical load through the knee. We can use PRP to change the biochemistry inside the joint itself. And we address diet and nutrition, because food feeds directly into that same inflammatory web. Each angle attacks a different part of the problem.
Here is the pattern I have noticed over the years: the patients who turn things around are not the ones with the least damage on their X-rays. They are the ones who also get their metabolic health moving — the weight, the diet, the strength work — all at the same time. That is the real shift. If inflammation is a driver, then arthritis is not something you are simply stuck with. It is something you can influence.
Arguably the most accessible lever of all is diet. The foods you choose can modify the same biomarkers that PRP affected. In one randomized controlled trial, an anti-inflammatory diet cut a key inflammatory marker by half.
If you have been told you are bone-on-bone and out of options, that is rarely the whole picture. You can schedule a consultation to discuss a plan built around your joint and your metabolic health, or browse more knee articles for related reading.
References
1. Synovial inflammation and the clinical symptoms of osteoarthritis. PubMed PMID 33453867
2. Osteoarthritis as a disease of the whole joint. PubMed PMID 27734845
3. Nervous system sensitization as a predictor of osteoarthritis pain. PubMed PMID 22961435
4. Circulating IL-1 beta and risk of radiographic knee osteoarthritis progression. PubMed PMID 21717421
5. Intra-articular IL-1 blockade in knee osteoarthritis. PubMed PMID 19248129
6. Twelve-month trial of a potent IL-1 inhibitor in knee osteoarthritis. PubMed PMID 30653843
7. Randomized trial of PRP versus corticosteroid versus oral anti-inflammatories in grade 3–4 knee osteoarthritis, with serum biomarker analysis. PubMed PMID 42231445
8. Randomized trial of semaglutide in obesity with knee osteoarthritis. PubMed PMID 39476339
9. GLP-1 receptor agonist use and risk of knee replacement surgery. PubMed PMID 42229941
10. Randomized controlled trial of an anti-inflammatory diet on inflammatory markers. PubMed PMID 28448087
Medical Disclaimer: This content is for educational purposes only and does not substitute for the medical advice of a physician. Always consult your healthcare provider before beginning any new treatment program. The information presented reflects the opinion of Dr. Jeffrey Peng and does not represent the views of his employers or affiliated hospital systems.
Comments